Company / Revenue
Akebia Therapeutics, Inc. Revenue History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$236.2M
FY2025
5-year range
$160.2M / $335.0M
FY2021-FY2025
Trend
+47.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 3 years of decline, reaching $236M.
Based on SEC 10-K filings.
$236M in FY2025 with a 5-year CAGR of +2.6%.
Improved from $195M to $236M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- +2.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.6%, indicating consistent growth.
- In FY2025, revenue increased 47.5% year-over-year.
- Peak revenue was recorded in FY2021.
- Lowest revenue in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $236.2M | +47.5% |
| FY2024 | $160.2M | -17.7% |
| FY2023 | $194.6M | -33.5% |
| FY2022 | $292.5M | -12.7% |
| FY2021 | $335.0M | +61.3% |
| FY2020 | $207.7M | +14.6% |
| FY2019 | $181.2M | +11706.3% |
| FY2018 | $1.5M | - |
| FY2015 | $0 | - |
| FY2014 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026